Attached files
file | filename |
---|---|
8-K - FENNEC PHARMACEUTICALS INC. | v205915_8k.htm |
ADHEREX
RESPONDS TO STOCK TRADING ACTIVITY
Chapel Hill, NC, December 17,
2010 - - Adherex Technologies Inc. (TSX:AHX, Pink Sheets: ADHXF), a
biopharmaceutical company focused on the development of eniluracil and
5-fluorouracil, is responding to a request from the Investment Industry
Regulatory Organization of Canada (IIROC) on behalf of the Toronto Stock
Exchange (TSX) following recent trading activity. Adherex is not aware of any
material undisclosed corporate developments to account for this
activity. Adherex's policy is not to comment on rumors or speculation, and
accordingly does not intend to comment further.
Except
for historical information described in this press release, all
other statements are forward-looking. Forward-looking statements are
subject to certain risks and uncertainties inherent in the Company's business
that could cause actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet regulatory standards
or receipt of required regulatory clearances or approvals, clinical results
may not be replicated in actual patient settings, protection offered
by the Company's patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available market
for the Company's products will not be as large as
expected, the Company's products will not be able to penetrate one or
more targeted markets, revenues will not be sufficient to fund further
development and clinical studies, the Company may not meet its future
capital needs, and its ability to obtain additional funding, as well as
uncertainties relative to varying product formulations and a multitude of
diverse regulatory and marketing requirements in different countries and
municipalities, and other risks detailed from time to time in the Company's
filings with the Securities and Exchange Commission including its Annual Report
on Form 10-K for the year ended December 31, 2009. Adherex
Technologies, Inc. disclaims any obligation to update these forward-looking
statements except as required by law.
For
a more detailed discussion of related risk factors, please refer to our public
filings available at www.sec.gov and
www.sedar.com.
For
further information, please contact:
Rosty
Raykov
Chief
Executive Officer
Adherex
Technologies Inc.
T: (919)
636-5144